We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+17.56%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.54B
AUM Growth
+$331M
Cap. Flow
-$396M
Cap. Flow %
-6.06%
Top 10 Hldgs %
39.82%
Holding
179
New
25
Increased
33
Reduced
89
Closed
18

Top Buys

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$49.7M
2
GEHC icon
GE HealthCare
GEHC
+$36.6M
3
MRNA icon
Moderna
MRNA
+$34.7M
4
BHVN icon
Biohaven
BHVN
+$33.4M
5
BSX icon
Boston Scientific
BSX
+$28M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$98.4M
2
UNH icon
UnitedHealth
UNH
+$64M
3
EVH icon
Evolent Health
EVH
+$36.8M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$34.5M
5
HUM icon
Humana
HUM
+$34.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.06%
2 Industrials 0.83%
3 Energy 0.03%
4 Consumer Discretionary 0.02%
5 Communication Services 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UNH icon
26
UnitedHealth
UNH
$382B
$72.7M 1.11%
138,152
-120,053
-46% -$64M
PACB icon
27
Pacific Biosciences
PACB
$416M
$71.8M 1.1%
7,317,128
+71,940
+1% +$588K
INSM icon
28
Insmed
INSM
$23.1B
$71M 1.09%
2,290,958
-871,777
-28% -$22.6M
IMCR icon
29
Immunocore
IMCR
$1.79B
$66.7M 1.02%
976,054
+956,204
+4,817% +$49.7M
RLAY icon
30
Relay Therapeutics
RLAY
$4.06B
$65.4M 1%
5,936,082
+1,051,082
+22% +$8.87M
OPCH icon
31
Option Care Health
OPCH
$3.38B
$65.3M 1%
1,938,807
-345,486
-15% -$10.6M
PODD icon
32
Insulet
PODD
$11.3B
$62.9M 0.96%
289,900
+25,541
+10% +$4.38M
TNDM icon
33
Tandem Diabetes Care
TNDM
$1.17B
$58.9M 0.9%
1,992,317
-150,452
-7% -$3.12M
CRSP icon
34
CRISPR Therapeutics
CRSP
$4.62B
$56.4M 0.86%
900,400
+2,000
+0.2% +$111K
ACCD
35
DELISTED
Accolade Inc
ACCD
$54.1M 0.83%
4,507,404
-20,519
-0.5% -$176K
IDXX icon
36
Idexx Laboratories
IDXX
$42.9B
$52.2M 0.8%
94,110
-20,331
-18% -$9.54M
EPIX
37
DELISTED
ESSA Pharma
EPIX
$52.1M 0.8%
7,898,583
– –
CRL icon
38
Charles River Laboratories
CRL
$11B
$51.5M 0.79%
217,756
-11,586
-5% -$2.28M
PEN icon
39
Penumbra
PEN
$12.5B
$51.1M 0.78%
203,046
-34,206
-14% -$7.56M
ELV icon
40
Elevance Health
ELV
$81.6B
$50.8M 0.78%
107,788
-66,099
-38% -$30.6M
EXEL icon
41
Exelixis
EXEL
$14B
$50.6M 0.77%
2,108,100
-267,825
-11% -$5.82M
AXSM icon
42
Axsome Therapeutics
AXSM
$12.4B
$50.6M 0.77%
635,372
+3,885
+0.6% +$260K
APLS
43
DELISTED
Apellis Pharmaceuticals
APLS
$49.2M 0.75%
821,800
+27,959
+4% +$1.42M
CDNA icon
44
CareDx
CDNA
$1.94B
$47.5M 0.73%
3,954,792
+13,994
+0.4% +$115K
BHVN icon
45
Biohaven
BHVN
$2.14B
$46M 0.7%
+1,075,000
New +$33.4M
HUM icon
46
Humana
HUM
$47.2B
$46M 0.7%
100,472
-69,574
-41% -$34.3M
BIO icon
47
Bio-Rad Laboratories Class A
BIO
$8.46B
$45.6M 0.7%
141,147
+6,817
+5% +$2.14M
INSP icon
48
Inspire Medical Systems
INSP
$1.46B
$43.9M 0.67%
215,600
+145,232
+206% +$23.5M
ALGN icon
49
Align Technology
ALGN
$12.1B
$43.7M 0.67%
159,407
-7,479
-4% -$1.77M
GEHC icon
50
GE HealthCare
GEHC
$27.8B
$41.4M 0.63%
535,184
+522,684
+4,181% +$36.6M
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q4 2023 Portfolio in Review

As of Q4 2023, Bellevue Group held 179 positions worth $6.54B, up 5.3% from $6.21B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Bellevue Group withdrew a net $396M in Q4 2023, closing 18 positions and reducing 89 holdings. Its most notable exit was Jazz Pharmaceuticals, an estimated $34.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Industrials and Energy.

Against the trend, Bellevue Group opened a new position in Biohaven worth $46M.

  • Bellevue Group's largest Q4 2023 buy was Biohaven: 1,075,000 shares worth $46M.
  • Bellevue Group added most to Immunocore in Q4 2023, an estimated $49.7M increase.
  • Bellevue Group's biggest Q4 2023 reduction was Vertex Pharmaceuticals, cutting an estimated $98.4M.
  • Bellevue Group fully exited Jazz Pharmaceuticals in Q4 2023, selling an estimated $34.5M.
  • Bellevue Group's ten largest holdings make up 40% of its $6.54B portfolio in Q4 2023.
  • Bellevue Group opened 25 new positions and closed 18 in Q4 2023.
  • Bellevue Group's portfolio value rose 5.3% quarter-over-quarter to $6.54B.

Based on Bellevue Group's 13F filing for Q4 2023, filed 14 Feb 2024.